VLS Valneva SE

Valneva SE Shareholding Declaration - March 2025

Valneva SE Shareholding Declaration - March 2025

VALNEVA

Declaration of shares and voting rights

March 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: April 3, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 162,521,524



 ordinary shares with a par value of €0.15 each
178,409,478 Double voting rights granted on 1,456 ordinary shares Between March 2 & March 28, 2025 178,285,156

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
03/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Valneva Strengthens Financial Position by Refinancing Debt with Pharma...

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business developmentCompany adjusts 2025 financial guidance and provides key business updates Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch